viruslik
particl
vlp
present
viral
antigen
nativ
conform
effect
recogn
immun
system
therefor
consid
suitabl
safe
vaccin
candid
mani
viral
diseas
demonstr
chimer
vlp
contain
rift
valley
fever
viru
rvfv
glycoprotein
g
n
g
c
nucleoprotein
n
gag
protein
moloney
murin
leukemia
viru
repres
effect
vaccin
candid
rift
valley
fever
deadli
diseas
human
livestock
longlast
humor
cellular
immun
respons
demonstr
mous
model
analysi
neutral
antibodi
titer
cytokin
secret
profil
vaccin
efficaci
studi
perform
mous
rat
lethal
challeng
model
result
high
protect
rate
taken
togeth
result
demonstr
replicationincompet
chimer
rvf
vlp
effici
rvfv
vaccin
candid
rift
valley
fever
viru
rvfv
devast
mosquitoborn
viral
zoonot
diseas
caus
seriou
morbid
mortal
human
livestock
rumin
rvf
character
substanti
mortal
young
anim
especi
lamb
fetal
deform
abort
flick
bouloy
gerd
swanepoel
coetzer
human
diseas
often
associ
benign
fever
lead
complic
case
retin
vascul
enceph
neurolog
deficit
hepat
necrosi
fatal
hemorrhag
fever
flick
bouloy
geisbert
jahrl
meegan
interestingli
human
case
fatal
rate
increas
significantli
last
sever
year
histor
less
infect
individu
develop
fatal
hemorrhag
fever
analysi
recent
outbreak
reveal
fatal
rate
human
labeaud
et
al
howev
differ
case
definit
accuraci
diseas
surveil
method
data
gather
methodolog
like
impact
number
rvfv
member
bunyavirida
famili
includ
virus
group
five
genera
orthobunyaviru
hantaviru
nairoviru
phleboviru
tospoviru
bunyavirus
envelop
virus
tripartit
singlestrand
rna
genom
neg
sometim
ambisens
polar
elliott
elliott
et
al
schmaljohn
hooper
larg
l
genom
rna
segment
encod
rnadepend
rna
polymeras
l
medium
segment
glycoprotein
precursor
posttransl
process
two
matur
spike
protein
new
convent
g
n
g
c
virus
nonstructur
protein
ns
small
segment
encod
nucleoprotein
n
virus
nonstructur
protein
ns
elliott
schmaljohn
hooper
rvfv
tradit
caus
recurr
outbreak
affect
human
rumin
predominantli
subsaharan
africa
spread
egypt
arabian
peninsula
alhazmi
et
al
anonym
balkhi
memish
madani
et
al
shoemak
et
al
recent
rvfv
circul
east
africa
caus
seriou
epidem
kenya
tanzania
somalia
sudan
report
comoro
island
labeaud
et
al
subsequ
expand
madagascar
south
africa
http
wwwfaoorgdoc
rvfv
prototyp
emergingreemerg
pathogen
classifi
categori
high
prioriti
pathogen
nation
institut
allergi
infecti
diseas
niaid
http
niaidnihgovtopicsbiodefenserelatedbiodefenseresearchcata
htm
center
diseas
control
cdc
bioterror
agent
http
wwwbtcdcgovagentagentlistcategoryasp
also
classifi
depart
health
human
servic
hh
unit
state
depart
agricultur
usda
overlap
select
agent
usda
lack
prophylact
therapeut
measur
potenti
humantohuman
transmiss
signific
threat
livestock
associ
rvfv
make
infect
pathogen
seriou
public
health
concern
endem
develop
countri
also
mani
nonendem
develop
countri
due
recent
bioterror
threat
clearli
illustr
need
rvfv
vaccin
research
develop
highli
attenu
treatment
cell
cultur
human
viru
isol
rvfv
caplen
et
al
vialat
et
al
recent
test
phase
ii
safetyefficaci
clinic
trial
clinicaltrialsgov
identifi
determin
safe
give
human
result
yet
publish
also
potenti
veterinari
applic
hunter
et
al
formalininactiv
rvfv
vaccin
develop
howev
licens
commerci
avail
pittman
et
al
provid
veterinarian
work
endem
area
high
contain
laboratori
worker
other
high
risk
contract
rvfv
pittman
et
al
unfortun
vaccin
expens
ii
difficult
produc
iii
short
suppli
iv
requir
larger
dose
rel
attenu
vaccin
three
initi
inocul
follow
booster
v
requir
continu
annual
booster
maintain
protect
immun
frankpetersid
kark
et
al
kark
et
al
niklasson
et
al
use
viruslik
particl
vlp
promis
approach
develop
safe
effici
rvfv
vaccin
express
structur
protein
mani
nonenvelop
envelop
virus
lead
format
vlp
garcea
gissmann
anderson
noad
roy
vlp
frequent
exhibit
morpholog
similar
wildtyp
wt
virus
johnson
chiu
sinc
vlp
tropism
similar
wt
viru
show
compar
cellular
uptak
intracellular
traffick
format
vlp
use
studi
viru
assembl
morphogenesi
bud
process
genom
packag
receptor
bind
viru
entri
bo
et
al
johnson
chiu
li
et
al
licata
et
al
overbi
et
al
schmitt
et
al
ye
et
al
especi
virus
classifi
high
contain
agent
eg
rvfv
ebolaviru
develop
vlp
system
practic
use
subsequ
work
perform
lower
biosafeti
condit
naslund
et
al
warfield
et
al
watanab
et
al
vlp
present
viral
antigen
nativ
conform
effect
recogn
immun
system
grgacic
grgacic
anderson
noad
roy
mani
promis
vaccin
candid
base
vlp
variou
stage
develop
includ
vaccin
candid
hepat
b
viru
hbv
human
papillomaviru
hpv
norwalk
viru
human
polyomaviru
bluetongu
viru
rotaviru
retrovirus
bunyavirus
filovirus
garcea
gissmann
grgacic
naslund
et
al
noad
roy
promis
attempt
gener
vlpbase
vaccin
mani
differ
anim
human
pathogen
encourag
us
evalu
rvf
vlp
vaccin
candid
rvfv
describ
gener
chimer
rvf
vlp
novel
concept
bunyavirus
optim
vlp
product
success
use
vaccin
candid
vaccin
efficaci
analyz
immunolog
studi
vaccin
mice
lethal
challeng
studi
two
differ
rodent
model
high
protect
rate
robust
longlast
immun
respons
vaccin
anim
demonstr
chimer
rvf
vlp
promis
approach
gener
safe
effici
rvfv
vaccin
rvf
vlp
gener
transient
transfect
cell
cell
constitut
express
moloney
murin
leukemia
viru
momlv
gag
protein
express
plasmid
encod
rvfv
glycoprotein
nucleoprotein
n
initi
focus
upon
gener
chimer
momlv
gagcontain
vlp
design
rvf
chimvlp
previous
shown
inclus
retrovir
gag
increas
uniform
quantiti
gheysen
et
al
haffar
et
al
hayn
et
al
rovinski
et
al
szecsi
et
al
stabil
hammond
et
al
vlp
addit
momlv
gag
protein
could
adjuvantlik
effect
rvf
vlp
harvest
tissu
cultur
supernat
h
posttransfect
concentr
tangenti
flow
filtrat
purifi
ultracentrifug
sucros
cushion
analyz
vlp
compon
sampl
fraction
sdspage
analyz
western
blot
use
rvfv
momlvspecif
antibodi
specif
signal
detect
confirm
presenc
rvfv
g
n
g
c
n
cellderiv
vlp
prepar
fig
first
three
panel
fig
well
momlv
gag
chimer
vlp
chimvlp
prepar
deriv
cell
fig
right
panel
note
gag
speci
detect
precursor
arrow
matur
proteolyt
process
speci
arrow
suomalainen
et
al
yoshinaka
et
al
transmiss
electron
microscopi
use
analyz
structur
gener
vlp
prepar
demonstr
uniform
natur
size
newli
synthes
vlp
form
intracellular
membran
presum
golgi
apparatu
base
studi
bunyaviru
glycoprotein
andersson
et
al
gerrard
nichol
haferkamp
et
al
bud
vesicl
analog
rvf
virion
fig
left
panel
rvfv
glycoprotein
spike
embed
vlp
membran
visibl
fig
right
panel
arrow
next
attempt
optim
rvf
vlp
product
use
express
plasmid
contain
codonoptim
rvfv
g
gene
suboptim
codon
usag
often
lead
ineffici
express
viral
protein
gene
mammalian
cell
barrett
et
al
haa
et
al
zhou
et
al
therefor
compar
amount
rvf
chimvlp
gener
cell
transfect
express
plasmid
encod
either
nativ
codonoptim
babcock
et
al
rvfv
g
gene
signific
differ
g
n
content
concentr
purifi
vlp
prepar
observ
separ
sdspage
analyz
western
blot
fig
howev
use
codonoptim
rvfv
g
appear
minim
benefici
effect
vlp
yield
similar
result
obtain
rvf
vlp
gener
cell
data
shown
therefor
subsequ
experi
codonoptim
sequenc
util
character
individu
compon
rvf
vlp
sucros
densiti
gradient
fraction
employ
techniqu
success
use
studi
elucid
specif
compon
vlp
prepar
hayn
et
al
ye
et
al
young
smith
ross
basi
approach
chimvlp
differ
densiti
vlp
base
differ
protein
composit
result
suggest
rvfv
g
n
momlv
gag
locat
within
particl
gener
chimvlp
data
shown
subsequ
immunoprecipit
experi
rvfv
g
n
antibodi
protein
agcoat
agaros
bead
confirm
result
data
shown
fig
neutral
antibodi
titer
rvf
vlpvaccin
mice
determin
plaqu
reduct
neutral
test
mous
sera
collect
three
immun
rvf
chimvlp
rvf
vlp
without
rvfv
n
ebolaviru
gppseudotyp
momlv
control
unimmun
mice
control
neutral
antibodi
titer
determin
reciproc
dilut
five
twofold
serial
dilut
sera
respect
neutral
antibodi
titer
consid
posit
lowest
initi
serum
dilut
result
n
prnt
reduct
number
plaqu
compar
viru
control
optim
rvf
vlp
product
differ
plasmid
ratio
determin
optim
chimer
rvf
vlp
product
cell
transfect
rvfv
g
express
plasmid
cotransfect
rvf
n
express
plasmid
indic
concentr
supernat
h
posttransfect
harvest
analyz
western
blot
use
antibodi
specif
rvfv
g
n
b
time
cours
experi
optim
rvf
vlp
yield
western
blot
analysi
perform
use
antibodi
specif
rvfv
g
n
g
c
indic
blot
rvf
chimvlp
vlp
harvest
select
time
posttransfect
densitometr
analysi
band
intens
display
maximum
band
intens
particular
blot
repres
histogram
western
blot
harvest
time
indic
gener
vlpbase
vaccin
candid
rvfv
mammalian
cell
laborintens
costli
regard
time
reagent
therefor
critic
perform
necessari
process
develop
establish
effici
manufactur
procedur
therefor
addit
optim
experi
perform
maxim
rvf
vlp
product
adher
mammalian
cell
differ
amount
express
plasmid
transfect
first
step
optim
vlp
product
three
differ
amount
rvfv
g
express
plasmid
use
analyz
increas
amount
rvfv
n
express
plasmid
rvf
chimvlp
harvest
interv
post
fig
antigenspecif
cytokin
secret
splenocyt
chimer
rvf
vlpvaccin
mice
measur
multiplex
analysi
tissu
cultur
supernat
splenocyt
harvest
h
postantigen
stimul
mice
immun
rvf
chimvlp
influenza
vlp
unvaccin
mous
subject
multiplex
bead
analysi
measur
select
cytokin
time
harvest
cytokin
measur
describ
top
left
panel
respect
data
splenocyt
harvest
control
mous
indic
red
bar
data
rvf
chimvlpvaccin
mice
indic
blue
bar
stimulatori
antigen
indic
graph
inset
show
result
main
graph
except
reduc
scale
yaxi
pgml
show
secret
detect
mani
point
mask
scale
requir
illustr
maxim
cytokin
signal
transfect
purifi
concentr
describ
fraction
sdspage
rvf
chimvlp
gener
measur
western
blot
analysi
use
antibodi
specif
rvfv
g
n
shown
fig
gener
rvf
chimvlp
strongli
affect
amount
rvfv
gand
nencod
express
plasmid
use
transfect
cell
high
amount
rvfv
n
express
plasmid
combin
lower
amount
rvfv
g
express
plasmid
molar
ratio
rvfv
n
g
result
best
vlp
yield
indic
g
n
signal
condit
also
result
detect
rvfv
n
vlp
prepar
data
shown
interestingli
analysi
also
show
rvf
vlp
gener
without
inclus
n
express
plasmid
transfect
rvfv
glycoprotein
express
plasmid
cell
fig
lane
previou
studi
demonstr
inclus
minigenom
encod
report
gene
use
tool
determin
vlp
titer
potenti
increas
n
content
vlp
overbi
et
al
therefor
segmentbas
minigenom
control
rna
polymeras
promot
billecocq
et
al
cotransfect
concert
rvfv
g
n
express
plasmid
determin
encapsid
minigenom
rvfv
n
subsequ
packag
bud
vlp
could
increas
overal
n
content
howev
signific
chang
either
vlp
yield
n
content
observ
data
shown
next
optim
transfect
scheme
rvfv
g
rvfv
n
express
plasmid
use
determin
optim
time
harvest
rvf
vlp
posttransfect
obtain
best
yield
focus
time
harvest
shorter
interv
clearli
save
substanti
time
reagent
therefor
time
cours
experi
perform
rvf
chimvlp
vlp
gener
cell
respect
harvest
interv
posttransfect
purifi
concentr
analyz
western
blot
antibodi
specif
rvfv
g
n
g
c
maximum
rvfv
g
n
g
c
signal
observ
h
time
point
indic
gener
vlp
optim
h
posttransfect
fig
addit
result
demonstr
six
harvest
h
posttransfect
recov
rvf
chimvlp
rvfv
vlp
produc
optim
express
strategi
transfect
condit
data
shown
plasmid
amount
plasmid
ratio
harvest
time
abl
gener
suffici
vlp
materi
subsequ
studi
next
address
question
whether
gener
rvf
vlp
use
replicationincompet
vaccin
candid
first
analyz
immun
respons
mice
neutral
antibodi
titer
durabl
cytokin
express
level
induc
rvf
vlp
subsequ
perform
protect
studi
two
differ
rodent
model
viral
vaccin
efficaci
often
correl
seroconversionspecif
gener
virusneutr
antibodi
khanam
et
al
ye
et
al
therefor
first
perform
durabl
studi
determin
whether
rvf
vlp
induc
longlast
rvfv
neutral
antibodi
mice
immun
subcutan
sc
three
time
rvfv
chimvlp
interv
blood
collect
day
post
vaccin
day
post
first
vaccin
plaqu
reduct
neutral
prnt
assay
mangiafico
et
al
use
rvfv
cell
perform
combin
serum
pfu
viru
neutral
antibodi
titer
consid
posit
highest
serum
dilut
inhibit
plaqu
compar
viru
control
titrat
shown
fig
neutral
titer
obtain
rvf
chimvlp
rvf
vlp
n
nucleoprotein
vaccin
mice
n
three
four
rvf
vlp
nvaccin
mice
develop
titer
one
seroconvers
detect
control
group
vaccin
unrel
momlvbas
vaccin
ebolaviru
gppseudotyp
momlv
control
nonvaccin
mice
control
high
neutral
titer
observ
month
postvaccin
indic
durabl
rvfv
vaccin
candid
warrant
evalu
rvf
vlpbase
vaccin
candid
next
studi
antigenspecif
secret
select
cytokin
splenocyt
isol
vaccin
mice
determin
whether
rvf
vlpbase
vaccin
elicit
humor
cellular
immun
respons
correl
vaccin
efficaci
live
challeng
model
wack
et
al
importantli
antivir
immun
often
correl
develop
cellular
immun
respons
warfield
et
al
splenocyt
harvest
mice
vaccin
three
time
rvf
chimvlp
day
day
post
final
vaccin
cultur
dish
cell
stimul
addit
heatinactiv
live
attenu
rvfv
strain
caplen
et
al
control
antigen
heatinactiv
influenza
viru
strain
supernat
sampl
taken
h
subject
cytokin
analysi
use
beadbas
multiplex
system
bioplex
biorad
splenocyt
vaccin
mice
secret
antigenspecif
cytokin
respons
stimul
unspecif
influenza
antigen
fig
blue
bar
splenocyt
control
unvaccin
mous
respond
either
stimulu
fig
red
bar
product
elicit
rvfvspecif
antigen
consist
humor
h
cellular
h
respons
chung
et
al
fromantin
et
al
interestingli
cytokin
level
peak
differ
time
poststimul
suggest
antigendepend
expans
cell
occur
vitro
immunolog
data
neutral
antibodi
titer
cytokin
secret
level
suggest
test
rvf
vlpbase
vaccin
candid
immunogen
immun
correl
alon
alway
predict
efficaci
live
challeng
model
therefor
group
mice
immun
day
select
vaccin
candid
chimer
vlp
produc
cell
chimvlp
vlp
produc
cell
rvfv
g
n
vlp
n
vlp
produc
cell
without
rvfv
n
vlp
n
fortysix
day
third
vaccin
day
post
first
vaccin
anim
challeng
pfu
rvfv
biosafeti
level
condit
observ
sign
diseas
day
fig
remain
four
mice
per
group
use
prnt
experi
fig
expect
anim
vaccin
pb
nonspecif
momlvbas
vaccin
control
respect
succumb
rvfv
challeng
within
first
day
demonstr
momlvspecif
compon
vaccin
protect
mice
rvfv
challeng
nine
vlp
n
vaccin
mice
surviv
lethal
challeng
three
surviv
immun
vlp
n
vaccin
result
show
protect
rvfv
challeng
depend
upon
presenc
rvfv
g
protein
enhanc
presenc
rvfv
n
chimvlpvaccin
mice
show
best
surviv
rate
mice
surviv
lethal
challeng
dose
signific
determin
use
mantelcox
test
signific
differ
exist
group
includ
chimvlp
vlp
n
p
vlp
n
vlp
n
p
three
vaccin
group
control
p
chimvlp
p
vlp
n
p
vlp
n
signific
differ
chimvlp
vlp
n
group
p
rat
present
anoth
import
altern
anim
model
rvfv
diseas
often
consid
relev
mice
anderson
anderson
et
al
bird
albarino
nichol
therefor
promis
data
obtain
mous
model
rvf
vlpbase
vaccin
efficaci
surviv
next
analyz
lethal
rat
challeng
model
object
test
best
vaccin
candid
base
immunolog
mous
protect
studi
minimum
number
anim
group
six
rat
immun
three
time
interv
chimer
rvf
vlp
vaccin
candid
steril
salin
control
sixtyseven
day
post
third
vaccin
day
post
first
vaccin
rat
challeng
high
dose
pfu
rvfv
examin
sign
diseas
day
bodi
weight
monitor
daili
indic
overal
health
rat
shown
fig
control
rat
succumb
diseas
day
postchalleng
rvf
chimvlp
vaccin
candid
protect
vaccin
rat
unvaccin
control
rat
show
rapid
substanti
weight
loss
succumb
challeng
wherea
rvfv
chimvlpvaccin
anim
gener
maintain
weight
throughout
cours
experi
fig
overal
immunolog
well
lethal
challeng
studi
two
differ
rodent
model
clearli
demonstr
rvf
vlpbase
vaccin
promis
concept
develop
vaccin
use
human
livestock
addit
experi
determin
minimum
vaccin
dose
vaccin
schedul
well
safeti
efficaci
studi
nonhuman
primat
requir
evalu
promis
vaccin
platform
structur
protein
mani
virus
assembl
vlp
grgacic
anderson
vlp
often
describ
efficaci
activ
immun
respons
convent
protein
immunogenssubunit
vaccin
immunogen
protein
compon
display
high
densiti
authent
conform
often
intact
biochem
function
effect
immunogen
garcea
gissmann
grgacic
noad
roy
enhanc
particul
natur
vlp
appear
optim
uptak
dendrit
cell
fifi
et
al
addit
safer
inactiv
attenu
viru
vaccin
usual
free
viral
genet
materi
therefor
encumb
possibl
safetyrel
drawback
includ
revers
recombin
reassort
stage
abil
develop
vlp
appear
limit
one
type
viru
viru
famili
complex
viru
particl
mimick
structur
viru
particl
allow
use
lower
dose
antigen
elicit
similar
protect
respons
compar
subunit
vaccin
noad
roy
addit
abil
stimul
bcellmedi
immun
respons
vlp
shown
highli
effect
stimul
prolif
cytotox
lymphocyt
respons
murata
et
al
paliard
et
al
schirmbeck
et
al
featur
vlpbase
vaccin
like
play
major
role
effect
vaccin
viral
diseas
welldocu
immunogen
vlp
like
facilit
interact
dendrit
cell
warfield
et
al
sever
vlpbase
vaccin
human
clinic
trial
fdaapprov
includ
hepat
b
viru
andr
safari
mcaleer
et
al
sitrin
et
al
trival
influenza
b
vaccin
flublok
cox
et
al
treanor
et
al
bird
flu
perron
et
al
human
papillomaviru
giannini
et
al
harper
et
al
harro
et
al
joura
et
al
human
immunodefici
viru
young
et
al
norwalk
viru
tacket
et
al
vlpbase
vaccin
promis
preclin
result
includ
vlp
sever
acut
respiratori
syndrom
sar
coronaviru
lokugamag
et
al
human
polyomaviru
goldmann
et
al
rotaviru
ciarlet
et
al
elattar
et
al
jiang
et
al
ebola
marburg
virus
swenson
et
al
swenson
et
al
warfield
et
al
warfield
et
al
warfield
et
al
addit
vlp
vaccin
also
import
agricultur
applic
includ
promis
vaccin
livestock
diseas
includ
bluetongu
noad
roy
roy
roy
et
al
roy
noad
footandmouth
li
et
al
remond
et
al
studi
undertaken
develop
vlp
bunyavirus
bunyamwera
vlp
gener
coexpress
g
n
g
c
nsm
addit
minigenom
system
bunyamwera
l
n
minigenom
mammalian
cell
use
identifi
viral
protein
compon
requir
viru
assembl
shi
et
al
shi
et
al
similarli
shown
express
recombin
g
n
g
c
glycoprotein
uukuniemi
uuk
viru
phleboviru
close
relat
rvfv
lead
assembl
bud
vlp
transfect
mammalian
cell
overbi
et
al
overbi
et
al
overbi
et
al
overbi
et
al
vlp
similar
structur
wt
viru
neutral
uukspecif
antibodi
howev
immunolog
vivo
studi
perform
determin
immunogen
liu
et
al
use
singl
recombin
baculoviru
express
rvfv
glycoprotein
g
n
g
c
n
protein
effici
gener
rvf
vlp
mammalian
cell
recent
demonstr
habjan
et
al
use
transfect
dna
encod
complet
rvfv
segment
well
rna
polymeras
l
nucleoprotein
n
gfpexpress
minigenom
naslund
et
al
et
al
show
rvf
vlp
use
vaccin
studi
three
intraperiton
inject
rvf
vlp
mice
induc
antibodi
titer
g
n
g
c
protein
result
develop
detect
nspecif
antibodi
importantli
vlp
protect
vaccin
mice
lethal
viru
challeng
pfu
wherea
surviv
unvaccin
control
group
gener
chimer
rvf
vlp
success
use
vaccin
candid
uniqu
field
bunyavirus
establish
effici
system
gener
rvfv
chimvlp
vlp
cell
fig
vlp
immunogen
indic
gener
neutral
antibodi
vivo
immun
mice
fig
antigenspecif
secret
immunerel
cytokin
splenocyt
vaccin
mice
fig
furthermor
vlpbase
vaccin
candid
partial
protect
mice
protect
rat
lethal
challeng
fig
interestingli
rvf
vlp
product
requir
express
two
glycoprotein
g
n
g
c
therefor
rvfv
n
requir
consist
find
overbi
et
al
abl
gener
uuk
bunyamwera
vlp
without
n
contradict
recent
find
suggest
rvf
vlp
could
gener
express
rvfv
glycoprotein
togeth
rvfv
n
part
minireplicon
system
possibl
explan
discrep
use
differ
express
system
eg
chicken
vs
immediateearli
cytomegaloviru
promot
lead
substanti
differ
amount
rvfv
g
produc
rvf
vlp
deriv
express
rvfv
g
requir
high
level
express
gener
rvf
vlp
lack
n
protein
facilit
ration
vaccin
design
gener
safe
highli
effici
rvfv
vaccin
follow
diva
differenti
infect
vaccin
anim
concept
differenti
vaccin
infect
individu
see
bird
et
al
capua
et
al
rvfvspecif
antibodi
n
protein
easili
detect
infect
individu
vaccin
candid
lack
n
antigen
facilit
diva
howev
studi
perform
eg
increas
vaccin
dose
differ
adjuv
increas
nlack
vlp
vaccin
effici
see
fig
chimvlp
contain
retrovir
gag
protein
either
momlv
simian
immunodefici
viru
siv
gag
antigen
interest
eg
influenza
hemagglutinin
neuraminidas
recent
describ
guo
et
al
hayn
et
al
unfortun
gener
rvf
chimvlp
complic
rvfv
g
momlv
gag
local
golgi
gerrard
nichol
schmaljohn
hooper
wasmoen
et
al
plasma
membran
soneoka
et
al
respect
mammalian
cell
howev
overexpress
rvfv
g
lead
g
n
g
c
local
cell
surfac
filon
et
al
gerrard
nichol
gerrard
nichol
liu
et
al
allow
gener
rvf
chimvlp
attempt
increas
rvfv
g
surfac
local
gener
chimer
rvfv
g
protein
contain
ectodomain
rvfv
g
transmembran
domain
cytoplasm
tail
momlv
env
ctermin
envelop
polyprotein
access
number
remov
put
golgi
retent
signal
rvfv
g
n
significantli
increas
rvfv
g
content
cell
surfac
demonstr
immunofluoresc
studi
result
increas
chimvlp
yield
data
shown
optim
vlp
product
import
abil
scaleup
gener
materi
requir
nonhuman
primat
livestock
studi
ultim
clinic
grade
vaccin
product
first
seen
fig
ratio
transfect
express
plasmid
rvfv
g
n
protein
influenc
vlp
yield
second
optim
gener
vlp
clearli
observ
n
plasmid
includ
increas
amount
n
express
plasmid
enhanc
gener
rvfv
vlp
similar
find
also
report
gener
uuk
vlp
overbi
et
al
addit
rvfvspecif
minigenom
significantli
increas
n
content
gener
vlp
despit
fact
vlp
abl
packag
minigenom
transfer
report
gene
activ
vlpinfect
cell
bouloy
r
flick
unpublish
data
contradict
previou
find
overbi
et
al
show
omiss
minigenom
lead
almost
nucleoprotein
incorpor
uuk
vlp
gener
vlp
optim
h
posttransfect
fig
determin
via
time
cours
experi
furthermor
multipl
harvest
time
period
posttransfect
result
higher
vlp
yield
compar
less
frequent
harvest
consist
previou
studi
show
multipl
harvest
ebolaviru
lassa
viru
chimvlp
yield
substanti
vlp
compar
singl
harvest
collect
interv
longer
h
data
shown
might
reflect
vlp
stabil
bind
produc
cell
inactiv
viral
vaccin
often
ineffect
elicit
neutral
antibodi
green
et
al
robust
vaccin
elicit
develop
neutral
antibodi
maintain
prolong
time
kan
et
al
prnt
gener
accept
protect
rvf
diseas
mice
peter
et
al
rat
anderson
et
al
anderson
slone
peter
hamster
niklasson
et
al
rhesu
macaqu
pittman
et
al
examin
neutral
antibodi
respons
human
subject
vaccin
inactiv
rvfv
vaccin
serum
neutral
antibodi
titer
primari
seri
three
inject
individu
titer
prnt
maintain
day
recipi
decreas
year
indic
durabl
might
issu
particular
vaccin
correl
develop
neutral
antibodi
protect
efficaci
rvfv
vaccin
also
shown
recent
sever
system
naslund
et
al
show
five
six
mice
vaccin
rvf
vlp
develop
neutral
antibodi
titer
prnt
eleven
vaccin
mice
protect
lethal
challeng
bird
et
al
show
rat
model
neutral
antibodi
titer
prnt
obtain
highli
attenu
rvfv
strain
lack
nss
nsm
gene
protect
lethal
challeng
demonstr
rvf
vlp
induc
neutral
antibodi
titer
detect
month
postimmun
fig
indic
robust
durabl
vlpbase
rvfv
vaccin
candid
interestingli
seen
fig
similar
neutral
antibodi
titer
gener
rvf
vlp
without
n
result
correl
vaccin
efficaci
mous
model
seen
fig
ncontain
rvf
vlp
substanti
efficaci
compar
vlp
lack
rvfv
n
demonstr
dna
vaccin
express
rvfv
orf
like
immun
rvfv
determin
respons
rvfv
g
spik
et
al
wallac
et
al
result
describ
suggest
n
might
repres
import
compon
efficaci
rvfv
vaccin
demonstr
rvfv
n
wallac
et
al
toscana
viru
relat
bunyaviru
n
gori
savellini
et
al
partli
protect
lethal
challeng
mice
interestingli
previou
passiv
transfer
studi
would
suggest
gener
neutral
antibodi
rvfv
g
n
g
c
predict
vaccin
efficaci
besselaar
blackburn
schmaljohn
et
al
rvf
vlp
without
n
suffici
gener
neutral
antibodi
see
fig
efficaci
mous
challeng
model
see
fig
furthermor
abl
demonstr
rvf
vlp
clearli
induc
antigenspecif
cytokin
secret
isol
splenocyt
vaccin
anim
fig
consist
result
ebolaviru
vlp
produc
mammalian
insect
cell
shown
stimul
secret
cytokin
dendrit
cell
bosio
et
al
ye
et
al
taken
togeth
measur
immun
correl
clearli
demonstr
vlp
immunogen
howev
vaccin
efficaci
studi
clearli
demonstr
potenc
vaccin
candid
therefor
employ
two
differ
rodent
model
determin
rvf
vlpbase
vaccin
efficaci
result
shown
fig
clearli
demonstr
rvf
vlp
vaccin
candid
partial
protect
mice
fulli
protect
rat
importantli
rvfv
challeng
rat
perform
log
higher
dose
often
report
literatur
see
bird
et
al
ensur
lethal
model
demonstr
vaccin
potenc
overal
novel
approach
use
chimer
rvf
vlp
vaccin
candid
yield
promis
immunolog
efficaci
data
two
differ
rodent
model
set
strong
preced
gener
efficaci
vaccin
rvfv
urgent
need
high
contain
laboratori
worker
indigen
peopl
endem
area
strateg
nation
stockpil
nation
veterinari
stockpil
protect
emerg
diseas
potenti
bioterror
event
rvfv
glycoprotein
g
express
plasmid
rna
purifi
vero
cell
use
qiaamp
viral
rna
mini
kit
qiagen
sequenc
chosen
sourc
glycoprotein
gene
allow
us
perform
initi
challeng
studi
lower
contain
condit
data
shown
cdna
prepar
use
rt
pcr
thermoscript
rtpcr
kit
oligo
dt
primer
kb
fragment
rvfv
segment
amplifi
cdna
use
phusion
hf
polymeras
phusion
high
fidel
pcr
mastermix
finnzym
rvfv
segmentspecif
primer
result
translat
rvfv
glycoprotein
precursor
avail
start
codon
facilit
optim
glycoprotein
express
collett
et
al
gerrard
nichol
suzich
et
al
next
kozak
sequenc
kozak
kozak
kozak
kozak
ad
immedi
atg
start
codon
pcr
amplif
use
phusion
hf
polymeras
follow
rvfv
segment
specif
oligo
pcr
product
clone
downstream
chicken
promot
pcagg
express
vector
kobasa
et
al
niwa
yamamura
miyazaki
kindli
provid
yoshihiro
kawaoka
univers
wisconsinmadison
usa
via
ecorixhoi
restrict
endonucleas
site
plasmid
dna
use
transfect
prepar
mgml
cesium
chlorid
cscl
purifi
univers
texa
medic
branch
utmb
recombin
dna
laboratori
galveston
tx
usa
codonoptim
codon
usag
describ
babcock
et
al
version
truncat
rvfv
glycoprotein
precursor
gene
synthes
genscript
piscataway
nj
usa
genbank
access
number
contain
kozak
sequenc
immedi
atg
start
codon
ecori
xhoi
restrict
site
subsequ
clone
step
gene
clone
pcagg
express
vector
via
ecorixhoi
restrict
endonucleas
site
plasmid
prepar
use
transfect
prepar
mgml
nucleobond
columnpurifi
macherynagel
natur
technolog
corpor
lincoln
ne
usa
rvfv
n
cdna
amplifi
rna
rtpcr
thermoscript
rtpcr
kit
primer
specif
segment
attatggtaccgccaccatggacaactatcaagagcttgcgatc
attatctcgagttaggctgctgtcttgtaagcctgagc
gener
product
kozak
sequenc
kozak
kozak
kozak
kozak
immedi
start
codon
kpni
xhoi
restrict
site
respect
product
clone
pcagg
express
vector
via
kpnixhoi
restrict
endonucleas
site
plasmid
dna
use
transfect
prepar
mgml
csclpurifi
recombin
dna
laboratori
seali
center
molecular
medicin
utmb
galveston
tx
usa
cell
cell
atcc
constitut
express
momlv
gag
pol
cultur
polydlysin
coat
mm
tissu
cultur
dish
falcon
cell
per
plate
dmem
gibco
fb
hyclon
penicillinstreptomycin
penstrep
uml
gibco
mm
lglutamin
gibco
co
overnight
media
remov
transfect
rvfv
g
n
express
plasmid
perform
use
lipofectamin
reagent
invitrogen
optimem
media
gibco
transfect
media
remov
h
posttransfect
replac
ml
dmem
media
plu
fb
penstrep
lglutamin
supernat
harvest
h
posttransfect
time
cell
cultur
ml
fresh
medium
supernat
pool
clarifi
centrifug
g
min
sampl
concentr
ml
via
tangenti
flow
filtrat
mini
filter
polyethersulfon
screen
type
c
millipor
purif
rvf
chimvlp
perform
centrifug
concentr
vlp
prepar
sucros
cushion
pb
use
beckman
ultraclear
ultracentrifug
tube
rotor
rpm
h
beckman
ultracentrifug
sampl
resuspend
ml
steril
nacl
baxter
rvf
vlp
cell
prepar
use
methodolog
rvfv
chimvlp
combin
ld
buffer
invitrogen
mm
dithiothreitol
dtt
sigma
heat
min
fraction
nupag
bistri
gel
invitrogen
protein
size
comparison
prestain
protein
molecular
weight
marker
seeblu
plu
invitrogen
use
protein
transfer
methanolactiv
pvdf
membran
invitrogen
subsequ
incub
h
nonfat
dri
milk
pb
membran
wash
min
pb
probe
primari
antibodi
h
room
temperatur
rt
monoclon
rvfv
g
n
antibodi
prosci
inc
poway
ca
usa
develop
g
n
specif
peptid
aedphlrnrpgkgh
monoclon
rvfv
g
c
antibodi
prosci
inc
develop
g
c
specif
peptid
qtrndktfaaskgn
rvfv
n
ascit
kindli
provid
dr
robert
b
tesh
univers
texa
medic
branch
usa
rabbit
polyclon
momlv
gag
antibodi
kindli
provid
dr
chinglai
wang
emori
univers
usa
h
rt
membran
wash
incub
either
apconjug
goat
antimous
antibodi
g
n
g
c
n
jackson
immunoresearch
west
grove
pa
usa
apconjug
rabbit
antigoat
momlv
gag
southern
biotech
birmingham
alabama
usa
membran
wash
describ
protein
band
visual
use
nbtbcip
solut
pierc
quantit
analysi
western
blot
analyz
use
imagej
softwar
burger
burg
imag
color
invert
background
subtract
averag
three
integr
densiti
read
per
band
determin
maximum
valu
set
equal
remain
valu
convert
percentag
rel
highest
read
tem
perform
univers
iowa
central
microscopi
research
facil
univers
iowa
usa
cell
fix
h
glutaraldehyd
acro
organ
geel
belgium
final
concentr
h
posttransfect
rvfv
g
n
express
plasmid
cell
wash
pb
ph
sodium
cacodyl
buffer
cell
fix
h
osmium
tetroxid
wash
sodium
cacodyl
buffer
subsequ
cell
rins
distil
water
min
treat
uranyl
acet
distil
water
min
cell
equilibr
ethanol
three
step
equilibr
ethanolepon
resin
epon
ted
pella
ethanolepon
h
final
epon
h
sampl
place
fresh
epon
h
block
subject
microtomi
gener
thin
section
section
counterstain
uranyl
acet
min
lead
citrat
reynold
min
section
imag
jeol
transmiss
electron
microscop
gatan
ultrascan
ccd
camera
sucros
densiti
gradient
fraction
rvf
vlp
purifi
cell
fraction
centrifug
rpm
h
discontinu
sucros
gradient
use
beckman
sw
ti
rotor
fraction
collect
dilut
ml
cold
pb
fraction
collect
centrifug
rpm
h
beckman
sw
ti
rotor
pellet
resuspend
ml
cold
pb
sampl
combin
mm
dtt
sigma
ld
sampl
buffer
invitrogen
fraction
sdspage
analyz
western
blot
momlv
gag
protein
detect
momlv
gag
antibodi
use
dilut
visual
alkalin
phosphataseconjug
rabbit
antigoat
igg
southern
biotech
dilut
immunoprecipit
rvf
chimvlp
momlv
gag
vlp
combin
rvfv
g
n
antibodi
protein
ag
plu
agaros
bead
santa
cruz
biotechnolog
santa
cruz
ca
incub
h
labquak
shaker
barnstead
thermo
scientif
supernat
bead
separ
centrifug
g
min
bead
wash
resuspens
ml
pb
centrifug
g
min
final
wash
bead
resuspend
pb
sd
lysi
buffer
invitrogen
dtt
ad
bead
supernat
heat
min
sampl
analyz
western
blot
use
rvfv
g
n
antibodi
momlv
gag
antibodi
immunoprecipit
result
analyz
measur
integr
densiti
specif
band
visual
western
analysi
use
imagej
softwar
mous
serum
sampl
separ
whole
blood
centrifug
microcentrifug
min
store
use
sera
dilut
mainten
medium
dmem
fb
penstrep
titrat
twofold
serial
dilut
step
equal
volum
rvfv
dilut
contain
approxim
plaqueform
unit
pfu
serum
dilut
mix
incub
h
co
confluent
monolay
cell
seed
plate
infect
virusserum
mixtur
h
incub
co
inocula
remov
well
overlaid
mixtur
one
part
gum
tragacanth
sigma
one
part
gibco
invitrogen
supplement
fb
sigma
penicillinstreptomycin
sigma
plate
incub
co
day
stain
crystal
violet
buffer
formalin
plate
wash
plaqu
enumer
dilut
rvfv
mainten
medium
use
posit
control
neutral
antibodi
titer
serum
consid
posit
lowest
initi
serum
dilut
result
n
prnt
reduct
number
plaqu
compar
viru
control
cytokin
secret
cultur
splenocyt
balbc
haplotyp
galactosyltransferaseko
transgen
mice
thall
et
al
kindli
provid
newlink
genet
corpor
immun
day
rvfv
chimvlp
spleen
harvest
three
mice
one
pbsvaccin
control
mous
day
post
final
vaccin
place
separ
petri
dish
steril
gey
balanc
salt
solut
sigma
spleen
slightli
minc
press
tissu
siev
bellco
cell
filter
filter
bd
falcon
strainer
centrifug
g
min
cell
harvest
resuspens
gey
solut
centrifug
underlay
lympholytem
cedarlan
lab
burlington
nc
usa
g
min
brake
splenocyt
harvest
interfac
wash
gey
solut
viabl
cell
plate
dish
corn
corn
ny
usa
cellsml
tcid
ml
heatinactiv
flu
viru
mouseadapt
strain
abdelmot
et
al
pfuml
heatinactiv
rvfv
caplen
peter
bishop
ad
test
well
cell
maintain
co
humid
supernat
harvest
analysi
h
poststimul
cytokin
cell
cultur
supernat
analyz
beadbas
multiplex
system
bioplex
biorad
accord
manufactur
instruct
secret
follow
assess
balbc
mice
describ
immun
subcutan
sc
total
protein
rvf
vlpbase
vaccin
candid
combin
sigma
adjuv
system
sigma
prepar
accord
manufactur
recommend
interv
challeng
mice
transfer
robert
e
shope
biosafeti
level
facil
univers
texa
medic
branch
galveston
intraperiton
ip
challeng
pfu
rvfv
mice
monitor
daili
sign
diseas
period
anim
experi
approv
iowa
state
univers
univers
texa
medic
branch
intern
anim
care
use
committe
iacuc
eightweekold
femal
wistarfurth
rat
harlan
laboratori
indianapoli
immun
interv
ip
ml
rvf
chimvlp
vaccin
candid
ml
steril
salin
baxter
deerfield
il
combin
sigma
adjuv
system
prepar
accord
manufactur
recommend
rat
transfer
robert
e
shope
facil
univers
texa
medic
branch
galveston
subcutan
sc
challeng
pfu
rvfv
day
post
final
booster
rat
monitor
daili
weight
chang
sign
diseas
anim
experi
approv
iowa
state
univers
univers
texa
medic
branch
iacuc
committe
